Elevated peripheral HIF-1α levels associated with higher fasting glucose and HbA1c in patients with type 2 diabetes mellitus
This systematic review and meta-analysis evaluated the relationship between peripheral HIF-1α protein expression and glycemic control in 5,979 patients with type 2 diabetes mellitus. The analysis focused on associations between elevated versus low peripheral HIF-1α levels and specific metabolic parameters, including fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), fasting insulin (FINS), and homeostatic model assessment of insulin resistance (HOMA-IR). No specific adverse events or discontinuations were reported in the safety data.
Results indicated a positive association between elevated peripheral HIF-1α and higher fasting plasma glucose, with a mean difference (MD) of 1.13 (95% CI [0.59, 1.67]). Similarly, increased HbA1c was associated with elevated HIF-1α, showing an MD of 0.93 (95% CI [0.63, 1.24]). Elevated HIF-1α levels also correlated with higher fasting insulin (MD = 1.13, 95% CI [0.24, 2.02]) and increased HOMA-IR (MD = 1.40, 95% CI [0.62, 2.18]).
Sensitivity analyses confirmed the robustness of these findings. However, geographic location significantly modified the association with fasting plasma glucose (p = 0.0105). The discordance between elevated systemic levels and known tissue-specific reductions suggests that peripheral HIF-1α may reflect a compensatory response to hypoxia rather than a primary driver of type 2 diabetes pathogenesis. Consequently, these biomarkers should not be interpreted as definitive causal indicators without further validation.